Boston Scientific (BSX) Stock
Global medical device company powering heart and urology care. Here's the price, business snapshot, and what's worth knowing about Boston Scientific in September 2026.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It’s Moving
BSX moves as investors balance a weaker outlook against insider and institutional buying
- Boston Scientific has been under pressure after investors digested a softer 2026 EPS outlook, which suggests margin and demand headwinds are still weighing on the story.
- Recent coverage points to a major cybersecurity-related disruption, adding operational uncertainty just as the stock has been trying to stabilize.
- Insider buying and fresh institutional accumulation have helped offset some of the negativity, signaling that longer-term investors still see value in the name.
BSX moves as investors balance a weaker outlook against insider and institutional buying
- Boston Scientific has been under pressure after investors digested a softer 2026 EPS outlook, which suggests margin and demand headwinds are still weighing on the story.
- Recent coverage points to a major cybersecurity-related disruption, adding operational uncertainty just as the stock has been trying to stabilize.
- Insider buying and fresh institutional accumulation have helped offset some of the negativity, signaling that longer-term investors still see value in the name.
Sixth Month Growth Performance
When is the next earnings date for BOSTON SCIENTIFIC CORP (BSX)?
Boston Scientific’s next earnings date is expected on October 28, 2026, before the market opens. The report should cover Q3 2026 results, based on the company’s usual quarterly reporting cadence. Exact timing can still shift if the company formally updates its schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific's stock with a target price of $81.74, indicating strong growth potential.
Financial Health
Boston Scientific is performing well with strong revenue and profit margins, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
